a
a
Weather:
No weather information available
HomeHealthShanton Receives Fast Track Designation from US FDA for Refractory Gout Program

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton’s lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ — Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has…

No comments

Sorry, the comment form is closed at this time.

Translate »